Management of Widespread Pain and Fibromyalgia

Peer reviewedPublisher PD

Predicting response to anti-TNFα therapy among patients with axial spondyloarthritis (axSpA) : results from BSRBR-AS

We are grateful to the staff of the British Society for Rheumatology Biologics Register in Axial Spondyloarthritis register and to the recruiting staff at the clinical centres, details of which are available at: https://www.abdn.ac.uk/iahs/research/epidemiology/spondyloarthritis.php#panel1011. We are grateful to Jonathan Lock for commenting on the manuscript. Funding: This work was supported by the British Society for Rheumatology (BSR) who have funded the BSRBR-AS. The BSR received funding for this from Pfizer, AbbVie and UCB. These companies receive advance copies of manuscripts for comments but have no input in to the topics for analysis in the register nor the work involved in undertaking analysis. Analysis of data was supported by the Versus Arthritis/Medical Research Council Centre for Musculoskeletal Health and Work [grant number 20665].Peer reviewe

Real-world evidence of TNF inhibition in axial spondyloarthritis : can we generalise the results from clinical trials?

Funding This work was supported by the British Society for Rheumatology (BSR) who funded the BSRBR-AS. The BSR received funding for this from Pfizer, AbbVie and UCB. These companies receive advance copies of manuscripts for comments but have no input in to the topics for analysis in the register nor the work involved in undertaking analysis. Analysis of data was supported by the Versus Arthritis/Medical Research Council Centre for Musculoskeletal Health and Work (grant number 20665).Peer reviewedPostprin

Scotland Registry for Ankylosing Spondylitis (SIRAS) – Protocol

Funding SIRAS was funded by unrestricted grants from Pfizer and AbbVie. The project was reviewed by both companies, during the award process, for Scientific merit, to ensure that the design did not compromise patient safety, and to assess the global regulatory implications and any impact on regulatory strategy.Publisher PD

Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue : Results from the BSRBR-AS registry and meta-analysis

We are grateful to the staff of the British Society for Rheumatology Biologics Register in Axial Spondyloarthritis register and to the recruiting staff at the clinical centres, details of which are available at: https://www.abdn.ac.uk/iahs/research/epidemiology/spondyloarthritis.php#panel1011. Funding: This work was supported by the British Society for Rheumatology (BSR) who have funded the BSRBR-AS. The BSR received funding for this from Pfizer, AbbVie and UCB. These companies receive advance copies of manuscripts for comments but have no input in to the topics for analysis in the register nor the work involved in undertaking analysis. Analysis of data was supported by the Versus Arthritis/Medical Research Council Centre for Musculoskeletal Health and Work [grant number 20665].Peer reviewedPublisher PD

Determining factors related to poor quality of life in patients with axial spondyloarthritis : results from the British Society for Rheumatology Biologics Register (BSRBR-AS)

The BSRBR-AS is funded by the British Society for Rheumatology who have received funding for this from Pfizer, AbbVie and UCB. These companies receive advance copies of manuscripts for comments, but made none in relation to this manuscript.Peer reviewedPublisher PD

Identifying Persons with Axial Spondyloarthritis At Risk of Poor Work Outcome : Results from the British Society for Rheumatology Biologics Register

MRC/Arthritis Research UK Centre for Musculoskeletal Health and Work (grant no: 20665 CI KW-B). The BSRBR-AS is funded by the British Society for Rheumatology who have received funding for this from Pfizer, AbbVie and UCB. These companies receive advance copies of manuscripts for comments. They have no input in determining the topics for analysis or work involved in undertaking it.Peer reviewedPostprin

Outcomes and treatment responses, including work productivity, among people with axial spondyloarthritis living in urban and rural areas : a mixed-methods study within a national register

ACKNOWLEDGEMENTS We are grateful to the staff of the British Society for Rheumatology Biologics Register in Axial Spondyloarthritis register who at the time of the study were Elizabeth Ferguson-Jones, Maureen Heddle, Nafeesa Nazlee and Barry Morris, and to the recruiting staff at the clinical centres, details of which are available at: https://www.abdn.ac.uk/iahs/research/epidemiology/spondyloarthritis.php#panel1011. FUNDING The BSRBR-AS is funded by the British Society of Rheumatology who have received funding for this, in part, from Pfizer, Abbvie and UCB. These companies receive advance copies of results but have no input in determining the topics for analysis or work involved in undertaking it. This work was conducted within the Versus Arthritis/Medical Research Council Centre for Musculoskeletal Work and Health (Grant No: 20665).Peer reviewedPublisher PD

Similar biologic drug response regardless of radiographic status in axial spondyloarthritis : data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry

Acknowledgements: We acknowledge Prof. Gary J. MacFarlane as chief investigator on the BSRBR-AS study. We are grateful to the staff of the BSRBR-AS register and to the recruiting staff at the clinical centres, details of which are available at www.abdn.ac.uk/bsrbr-as. H.M.O. designed the study proposal. X.M. analysed the data and wrote the manuscript, with significant input from all co-authors. G.T.J. is deputy chief investigator on the BSRBR-AS study and together with L.D. discussed results and provided input into drafts of the manuscript. The study was approved by the National Research Ethics Service Committee North East-County Durham and Tees Valley (reference 11/NE/0374) and informed consent was obtained from all participants. Funding: This work was supported by a research grant from the FOREUM Foundation for Research in Rheumatology. The BSRBR-AS is funded by the British Society for Rheumatology, which received funding for this from Pfizer, AbbVie and UCB. They have no input in determining the topics for analysis or work involved in undertaking it.Peer reviewedPublisher PD

The role of metrology in axSpA : does it provide unique information in assessing patients and predicting outcome? Results from the BSRBR-AS registry

ACKNOWLEDGMENTS We thank the staff who contributed to running the BSRBR-AS register and we also thank the recruiting staff at the clinical centers, details of which are available at: www.abdn.ac.uk/bsrbr-as.Peer reviewedPostprin